ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Hiromichi Katakura
Hiromi Wada
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katakura, H.
Right arrow Articles by Wada, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katakura, H.
Right arrow Articles by Wada, H.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2002;73:1060-1064
© 2002 The Society of Thoracic Surgeons

Original article: general thoracic

Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer

Hiromichi Katakura, MDa, Fumihiro Tanaka, MDa, Hiroki Oyanagi, MDa, Ryo Miyahara, MDa, Kazuhiro Yanagihara, MDa, Yosuke Otake, MDa, Hiromi Wada, MD*a

a Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, Japan

Accepted for publication December 2, 2001.

* Address reprint requests to Dr Wada, Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 53, Sakyo-ku, Kyoto 606-8507, Japan
e-mail: wadah{at}kuhp.kyoto-u.ac.jp

Background. Clinical significance of the status of nm23 gene, originally identified as an antimetastatic gene, in non-small cell lung cancer remains unestablished, whereas many clinical studies have demonstrated that reduced nm23 expression is correlated with tumor progression and poor prognosis in a variety of malignant tumors such as breast carcinoma.

Methods. nm23 expression was examined immunohistochemically in a total of 117 patients with completely resected pathologic stage I non-small cell lung cancer.

Results. nm23 expression was positive in 73 (62.4%) patients, and there was no correlation between nm23 expression and age, sex, performance status, pathologic T factor, histologic type, or degree of cancer cell differentiation. The 5-year survival rates of nm23-positive and nm23-negative patients were 79.7% and 57.8%, respectively, demonstrating a significantly poorer prognosis in nm23-negative patients (p = 0.013), which was confirmed by a multivariate analysis. nm23 was not correlated with the incidence of apoptosis, proliferative activity, or p53 status.

Conclusions. nm23 expression was a significant factor for predicting a favorable prognosis, suggesting antimetastatic potential of the nm23 gene in non-small cell lung cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. I. Pass, Z. Liu, A. Wali, R. Bueno, S. Land, D. Lott, F. Siddiq, F. Lonardo, M. Carbone, and S. Draghici
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
Clin. Cancer Res., February 1, 2004; 10(3): 849 - 859.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.